These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8835058)

  • 41. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems.
    Carvajal A; Macias D; Sáinz M; Ortega S; Martín Arias LH; Velasco A; Bagheri H; Lapeyre-Mestre M; Montastruc JL
    Drug Saf; 2006; 29(2):143-9. PubMed ID: 16454541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin].
    Mantell G
    Therapie; 1992; 47(2):161-4. PubMed ID: 1412144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
    Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F
    Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Side effects of HMG-CoA Reductase inhibitors in placebo-controlled trials ].
    Kreutzkamp B
    Med Monatsschr Pharm; 2015 Feb; 38(2):73; discussion 74. PubMed ID: 26376546
    [No Abstract]   [Full Text] [Related]  

  • 46. HMG CoA reductase inhibitors and quality of life.
    Downs JR; Oster G; Santanello NC
    JAMA; 1993 Jun 23-30; 269(24):3107-8. PubMed ID: 8505809
    [No Abstract]   [Full Text] [Related]  

  • 47. Statins: in the beginning.
    Lyons KS; Harbinson M
    J R Coll Physicians Edinb; 2009 Dec; 39(4):362-4. PubMed ID: 20509462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sleep disturbance and HMG CoA reductase inhibitors.
    Black DM; Lamkin G; Olivera EH; Laskarzewski PM; Stein EA
    JAMA; 1990 Sep; 264(9):1105. PubMed ID: 2384934
    [No Abstract]   [Full Text] [Related]  

  • 49. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation?
    Sinzinger H
    Atherosclerosis; 2000 Mar; 149(1):225. PubMed ID: 10799017
    [No Abstract]   [Full Text] [Related]  

  • 50. Lovastatin-associated dermatomyositis.
    Rodriguez-Garcia JL; Serrano Commino M
    Postgrad Med J; 1996 Nov; 72(853):694. PubMed ID: 8944218
    [No Abstract]   [Full Text] [Related]  

  • 51. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.
    Grimbert S; Pessayre D; Degott C; Benhamou JP
    Dig Dis Sci; 1994 Sep; 39(9):2032-3. PubMed ID: 8082513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lovastatin and peripheral neuropathy.
    Ahmad S
    Am Heart J; 1995 Dec; 130(6):1321. PubMed ID: 7484806
    [No Abstract]   [Full Text] [Related]  

  • 53. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease.
    Golomb BA; Evans MA
    Med J Aust; 2007 Aug; 187(4):253. PubMed ID: 17708735
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of humidity-dependent changes in crystal structure on the solid-state fluorescence properties of a new HMG-CoA reductase inhibitor.
    Brittain HG; Ranadive SA; Serajuddin AT
    Pharm Res; 1995 Apr; 12(4):556-9. PubMed ID: 7596991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperkalemia during treatment with HMG-CoA reductase inhibitor.
    Edelman S; Witztum JL
    N Engl J Med; 1989 May; 320(18):1219-20. PubMed ID: 2710198
    [No Abstract]   [Full Text] [Related]  

  • 56. Association between statins use and erectile dysfunction.
    Zhao SG; Han QF; Li T; Yao HC
    Int J Cardiol; 2017 Jul; 239():16. PubMed ID: 28560963
    [No Abstract]   [Full Text] [Related]  

  • 57. EAS Task Force gives practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients.
    Stock JK
    Atherosclerosis; 2021 Jul; 329():32-35. PubMed ID: 34130861
    [No Abstract]   [Full Text] [Related]  

  • 58. Gemfibrozil-induced impotence.
    Figueras A; Castel JM; LaPorte JR; Capellà D
    Ann Pharmacother; 1993; 27(7-8):982. PubMed ID: 8364294
    [No Abstract]   [Full Text] [Related]  

  • 59. Impotence associated with cinnarizine.
    Sempere AP; Garcia FM; Duarte J; Mataix AL; Coria F; Claveria LE
    Ann Pharmacother; 1993 Mar; 27(3):370. PubMed ID: 8453180
    [No Abstract]   [Full Text] [Related]  

  • 60. Gemfibrozil-induced impotence.
    Pizarro S; Bargay J; D'Agosto P
    Lancet; 1990 Nov; 336(8723):1135. PubMed ID: 1978015
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.